

# Sophie Duraffour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2988539/publications.pdf>

Version: 2024-02-01

20  
papers

2,739  
citations

623574

14  
h-index

752573

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

5302  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-time, portable genome sequencing for Ebola surveillance. <i>Nature</i> , 2016, 530, 228-232.	13.7	1,179
2	Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. <i>Lancet</i> , The, 2015, 386, 857-866.	6.3	715
3	Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. <i>Science</i> , 2019, 363, 74-77.	6.0	201
4	Unique human immune signature of Ebola virus disease in Guinea. <i>Nature</i> , 2016, 533, 100-104.	13.7	170
5	Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. <i>Genome Biology</i> , 2017, 18, 4.	3.8	115
6	Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. <i>Tropical Medicine and International Health</i> , 2021, 26, 621-631.	1.0	64
7	Phylogeography of Lassa Virus in Nigeria. <i>Journal of Virology</i> , 2019, 93, .	1.5	49
8	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 195-202.	1.9	38
9	Evaluation of RealStar Reverse Transcription-Polymerase Chain Reaction Kits for Filovirus Detection in the Laboratory and Field. <i>Journal of Infectious Diseases</i> , 2016, 214, S243-S249.	1.9	33
10	Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study. <i>The Lancet Global Health</i> , 2021, 9, e469-e478.	2.9	30
11	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 507-516.	4.6	26
12	Detection of Marburg Virus Disease in Guinea. <i>New England Journal of Medicine</i> , 2022, 386, 2528-2530.	13.9	26
13	Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, S496-S503.	1.9	25
14	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	2.6	15
15	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. <i>Scientific Reports</i> , 2020, 10, 8724.	1.6	14
16	Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e32-e40.	3.4	13
17	Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 876-886.	4.6	8
18	A Sporadic and Lethal Lassa Fever Case in Forest Guinea, 2019. <i>Viruses</i> , 2020, 12, 1062.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. <i>BMJ Open</i> , 2020, 10, e036936.	0.8	4
20	Fc $\gamma$ 3-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0007522.	1.8	4